(Q36045265)

11 August 2017

1 reference

title

Strategic challenges in neurotherapeutic pharmaceutical development (English)

1 reference

11 August 2017

Christopher C Gallen

1

1 reference

11 August 2017

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

1

1 reference

11 August 2017

165-180

1 reference

Hepatotoxicity of the thiazolidinediones

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Rational design and engineering of therapeutic proteins

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

The price of innovation: new estimates of drug development costs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Protection against ischemic brain injury by protein therapeutics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Thalassemia and abnormal hemoglobin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Recent advances in cystic fibrosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Target-oriented and diversity-oriented organic synthesis in drug discovery

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Drug discovery: a historical perspective

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Returns to R&D on new drug introductions in the 1980s

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534921

Delivering the power of discovery in large pharmaceutical organizations.

2 October 2017

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.1.165

Surviving a knockout blow

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.1.165

Returns on research and development for 1990s new drug introductions

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.1.165

Realism in drug discovery-could Cassandra be right?

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.1.165

Drug development: improving the process

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15717016

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reverse-engineering clinical biology. A peacetime dividend yields drug trials on virtual patients.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15717016

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/15717016

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1602/NEURORX.1.1.165

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

PMCID

534921